March 2011

TABLE OF CONTENTS

Fast-Dispersing Dosage Forms for the Pediatric Market

Susan Banbury, PhD; and Karen MacGregor, PhD; suggest growth in the oral drug delivery market is being driven in part by innovative oral formulations that offer the stability, dose accuracy, and convenience of solid oral dosage forms with the dosing ease of a liquid to facilitate patient compliance, an important consideration in pediatric delivery.

 

Tackling the Challenge of Nucleic Acid Delivery: Progress & New Approaches

James J. Cunningham, PhD; Louis S. Crocker, PhD; and Anthony Leone, PhD; highlight some of the most promising approaches in nucleic acid delivery, despite the significant challenges facing this endeavor.

 

The Use of Surface-Modified Nanoparticles to Facilitate the Processing of Oral Solid Dosage Forms

Joseph Beaurline; John Hedenstrom, PhD; Jacqui Ganser, MS; Jimmie Baran, PhD; and Fred LaPlant, PhD; conduct experiments that prove surface-modified nanoparticles enhance powder processing as characterized by improved flow and increased bulk/tapped density.

 

Prefilled Syringes Pinpoint Stability, Compatibility & Safety

Contributor Cindy H. Dubin spoke with some of the PFS market’s leading companies to find out how they are evolving the technology to tackle pharma’s drug performance challenges, patients’ need for convenience, and government safety requirements.

 

Lifecycle Management & Differentiation Through Injectable Delivery Systems

Graham Reynolds believes the inter-dependence of the packaging and delivery system needs to be carefully considered at an early stage, and a thorough understanding of both is key to ensuring a successful drug/delivery system combination.

 

Cetero Research: Addressing Today’s Challenges in Drug Development

Drug Development Executive: Dr. Troy W. McCall, Cetero’s CEO, focuses on innovative advancements to address drug development challenges and how CROs must build capabilities and expertise to offer value to sponsors in a constantly evolving, yet uncertain, industry environment.

 

RXi & EyeGate Set Their Sights on the Retinal Disease Market

Partnership Spotlight: Contributor Cindy H. Dubin interviews Mr. Noah Beerman, President and CEO of RXi Pharmaceuticals, and Mr. Stephen From, President and CEO of EyeGate Pharma, on why they believe together their companies are well positioned to compete successfully in the ophthalmologic market.

 

DEPARTMENTS

  

Market News & Trends

 

Excipient Update

Permeability Study on the Coating Film Consisting of CA-398-10 NF/EP & CA- 320S NF/EP

 

Combination Update

FDA Regulatory Update: Top 10 Policy Development Issues for 2011 & What May Stand in the Way of Advancing Them

 

Technology Showcase

COVER

FEATURES